Degarelix as a new antiangiogenic agent for metastatic colon cancer?

作     者：Francois Ghiringhelli Nicolas Isambert Sylvain Ladoire 

作者机构：Unite Mixte de Recherche 866Institut National de la Sante et de la Recherche Medicale/Universite de Bourgogne21000 DijonFrance Departement of Oncologie MedicaleCentre Georges Francois Leclerc21000 DijonFrance 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2013年第19卷第5期

页      面：769-772页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Colon cancer Degarelix Chemotherapy Angiogenesis Antiangiogenic agents 

摘      要：Recently,follicle stimulating hormone receptor was found to be selectively expressed by endothelial cells on tumor-associated blood vessels in a wide range of human *** this context,we hypothesized that degarelix,a new gonadotropin-releasing hormone receptor antagonist developed for patients with prostate cancer,may have antiangiogenic effects via its capacity to block follicle stimulating hormone(FSH)production. We report the case of a patient with metastatic colon cancer exhibiting tumor progression after failure of all conventional chemotherapeutic *** addition of degarelix to the last chemotherapeutic regimen was proposed as compassionate *** induced a rapid decrease in FSH *** treatment induced radiological stabilization and carcinoembryonic antigen stabilization during 1 ***-enhanced ultrasonography demonstrated reduction of tumor *** case represents the first report of an antitumoral effect of degarelix in metastatic colon cancer and suggests an antiangiogenic property of this drug.